Peng Zhekang, Xu Jiqian, He Yajun, Sun Deyi, Shang You
Department of Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, Hubei, China. Corresponding author: Shang You, Email:
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2022 Jun;34(6):666-669. doi: 10.3760/cma.j.cn121430-20210930-01432.
Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated host response to infection. Most patients with sepsis underwent a state of immune suppression after surviving the acute inflammatory response, and were susceptible to secondary nosocomial infections, leading to a prolonged hospitalization and increased mortality rate. Myeloid-derived suppressor cells (MDSCs), a heterogeneous population with immunosuppressive activities, can contribute to the development of immunosuppression in patients with cancer and inhibit the host immune response, but the characteristics of MDSCs and their functional mechanism has not been fully addressed in the development of sepsis-induced immunosuppression. Thus, this review will summary the new findings on the mechanisms of MDSCs in septic immunosuppressionin order to provide ideas and directions for targeting MDSCs as treatment of septic immunosuppression.
脓毒症被定义为由宿主对感染的失调反应引起的危及生命的器官功能障碍。大多数脓毒症患者在度过急性炎症反应后会进入免疫抑制状态,并且易患继发性医院感染,导致住院时间延长和死亡率增加。髓系来源的抑制细胞(MDSCs)是一类具有免疫抑制活性的异质性细胞群,可促进癌症患者免疫抑制的发展并抑制宿主免疫反应,但在脓毒症诱导的免疫抑制发展过程中,MDSCs的特征及其功能机制尚未完全阐明。因此,本综述将总结MDSCs在脓毒症免疫抑制机制方面的新发现,以便为将MDSCs作为脓毒症免疫抑制治疗靶点提供思路和方向。
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2022-6
Cytokine Growth Factor Rev. 2023-2
Biomed Res Int. 2014
Front Immunol. 2019-2-27
Int Immunopharmacol. 2022-3
Immun Inflamm Dis. 2023-8